Last updated: July 14, 2026
- Case: Salix Pharmaceuticals, Inc. v. Cipla USA, Inc., 1:24-cv-10213 (D. Mass.).
- Core posture: IP enforcement by Salix against Cipla tied to a generic entry challenge under the Hatch-Waxman framework, with claims directed at Orange Book-listed patents for Salix’s relevant marketed product(s).
- Actionable impact: The case affects launch timing risk for Cipla and any downstream ANDA applicants, because the court’s rulings on invalidity/unenforceability/non-infringement and any injunction/settlement terms determine whether Cipla can market the at-issue dosage form before patent and/or exclusivity expiration.
What patents are asserted in Salix Pharmaceuticals v. Cipla (1:24-cv-10213)?
Short answer: The asserted patents are those listed in the FDA Orange Book for the Salix drug whose ANDA filing triggered the suit, typically with one or more patents in categories including composition, formulation, method-of-use, and/or manufacturing/covering use.
Which Orange Book patents drive the litigation?
Featured snippet-level framing for docket readers:
- Salix’s complaint in Hatch-Waxman actions usually asserts Orange Book patents listed for the reference listed drug (RLD).
- The case number indicates a 2024 federal filing, consistent with disputes over Paragraph IV certifications and the statutory timing for potential launch.
What patent classes typically appear in Salix patent estates?
In Salix’s portfolio (gastrointestinal and IBD-adjacent brands), asserted families frequently include:
- Formulation patents (excipients, dosage architecture, coatings).
- Method-of-use patents tied to dosing regimens, indications, or drug administration constraints.
- Manufacturing method or process patents that can survive generic equivalence arguments.
What is the litigation timeline for 1:24-cv-10213?
Short answer: A 2024 filing indicates an ANDA-related dispute flow that begins with an ANDA notice and culminates in federal pleadings within the statutory 45 to 30 day windows after notice, followed by an injunction motion schedule if seeking case-resolved relief.
Key procedural milestones (what to expect in this docket)
For high-intent docket work, the operative sequence is standard:
- Salix files for patent infringement in federal court.
- Cipla answers with defenses: invalidity, non-infringement, and possible unenforceability (inequitable conduct, prosecution history estoppel, patent misuse).
- Claim construction occurs on a schedule set by the court’s case management order.
- Parties litigate Paragraph IV patent validity and infringement through expert discovery.
- If the court finds infringement of a valid asserted claim, the typical outcome is an injunction preventing launch during patent term.
What does the case say about infringement, non-infringement, and invalidity?
Short answer: The litigation generally centers on whether Cipla’s proposed ANDA product infringes Salix’s asserted claims and whether those claims are invalid under §§ 102, 103, 112, or unenforceable for inequitable conduct.
How Cipla typically attacks Salix claims in ANDA suits
Cipla’s defenses in ANDA cases usually include:
- Non-infringement via lack of claim elements in the proposed product.
- Invalidity via anticipation or obviousness against prior art, including patent and non-patent literature.
- Section 112 arguments around indefiniteness and written description/enablement.
- Indefiniteness in claim terms and claim construction disputes.
How Salix typically frames infringement
Salix typically argues:
- Cipla’s ANDA labels and formulation/proposed specs map to each asserted claim element.
- Any minor formulation variations do not avoid infringement if the asserted claim is drafted broadly enough to cover functional equivalents.
What is the Paragraph IV posture and how does it affect launch?
Short answer: A suit on an ANDA filing in 2024 almost always implies Paragraph IV certification to at least one Orange Book patent, making the statutory 30-month stay and any injunction analysis central to whether Cipla can launch.
How the 30-month stay functions in this case
In practice:
- If Cipla filed an ANDA with Paragraph IV certifications and did not settle before the 45-day notice window expiration, the case typically triggers a 30-month stay from the ANDA submission date, unless a court rules earlier.
- If patents are held valid and infringed, Cipla’s launch typically stays blocked until expiration of the adjudicated patents.
What injunction or settlement outcomes are possible in Salix v. Cipla?
Short answer: In Hatch-Waxman disputes, the two highest-probability outcomes are (i) an injunction if the court finds infringement of at least one valid claim, or (ii) a settlement that resolves infringement findings and establishes a launch date and licensing terms.
Common settlement structures
Patent settlements in this context often include:
- Agreed launch date tied to patent expiration.
- Carve-outs allowing non-infringing product variants.
- Patent license for specific claims, sometimes limited to defined strengths or dosage forms.
How strong is Salix’s patent estate for the asserted product?
Short answer: Strength in ANDA litigation is driven by claim breadth, priority date advantage, and survivability against prior art in the asserted families. Salix’s estates in GI therapeutics often include multi-layer coverage that can make “design-around” harder.
Strength indicators used in this docket class of cases
- Whether asserted claims are supported by early priority and broad specification.
- Whether claim terms have survived prior PTAB or district court litigation in related families.
- Whether multiple patents are asserted against the same ANDA, enabling partial win leverage even if some claims fall.
Which patents are likely to be most important if multiple families are asserted?
Short answer: The “most important” patents are those that (a) cover the core dosage form and formulation and (b) are likely to be adjudicated first, because they affect the feasibility of any launch carve-out.
Typical decision drivers
- The court’s claim construction determines which patents survive summary judgment.
- Expert testimony on infringement maps proposed product attributes to claim limitations.
- Prior art strength determines whether the asserted claims are narrowed or invalidated.
Does this litigation create biosimilar or exclusivity risk?
Short answer: No biosimilar framework applies. This is a Hatch-Waxman small-molecule/ANDA-style dispute, not a Biologics License Application (BLA) case.
Exclusivity angles that can still matter
Even if patents are challenged, FDA exclusivity can matter:
- 180-day exclusivity for first-filing ANDAs can be a separate gating issue.
- If exclusivity is impacted by forfeiture or court rulings, it can influence commercial timing.
What FDA regulatory status issues are implicated?
Short answer: The suit ties to ANDA regulatory readiness for market entry, including certification to Orange Book patents and potential design changes to avoid infringement.
What to watch on the FDA side
- ANDA approval status (tentative or final)
- Labeling carve-outs tied to disputed indications or dosing
- Any amendment to Paragraph IV certifications or product composition
How does the Salix v. Cipla case compare with other Salix ANDA patent fights?
Short answer: Comparable Salix litigations typically follow the same pattern: asserted Orange Book families, heavy claim-construction work, and launch timing leverage via injunction/settlement.
Competitive landscape implications
- If Salix wins on key claims, other ANDA challengers face reduced feasibility for near-term entry.
- If Cipla wins or the asserted claims are narrowed/invalidated, it can open space for broader generic entry across that product class.
Key takeaways
- Salix Pharmaceuticals, Inc. v. Cipla USA, Inc., 1:24-cv-10213, is an ANDA-driven patent infringement case that determines whether Cipla can market a generic version of a Salix Orange Book-listed drug before patent expiration.
- The case turns on the standard triad: infringement of asserted Orange Book claims, validity of those claims, and potential unenforceability defenses.
- The practical business outcome is launch timing. The court’s rulings or any settlement will set the effective market entry date and the scope of any licensed or non-licensed workaround.
FAQs
1) What is the standard remedy Salix seeks in ANDA patent cases like this?
An injunction blocking FDA approval/launch of the generic product during the term of any adjudicated valid and infringed patent, plus damages if infringement is found.
2) Does a Paragraph IV filing automatically mean an injunction?
No. Paragraph IV is the trigger for litigation; injunction depends on the court’s infringement and validity determinations (or a settlement).
3) Can Cipla avoid liability by changing formulation or labeling?
Potentially, but the generic product must still satisfy ANDA requirements. Design changes can trigger additional litigation if they are still captured by claim scope.
4) What happens if some asserted patents are invalidated but others survive?
Cipla can potentially launch only if it is cleared as to all patents blocking entry. Surviving patents can still bar launch.
5) What document is most important for mapping risk before the merits ruling?
The complaint’s asserted-patent list and the claim charts or infringement contentions that map Cipla’s proposed product attributes to each claim.
References
- U.S. District Court, District of Massachusetts. Salix Pharmaceuticals, Inc. v. Cipla USA, Inc., No. 1:24-cv-10213 (docket and filings).
